Phage Pharma appoints David Jackson
pharmafile | July 27, 2010 | Appointment | Manufacturing and Production | Phage, appointment, manufacturing and production
US clinical-stage development and manufacturing company Phage Pharmaceuticals has appointed David Jackson VP of operations planning.
He will be responsible for oversight of the company’s cGMP-certified therapeutic protein manufacturing facility in San Diego and reports to chief executive Robert Beckman.
Prior to joining Phage, David was VP of process development and manufacturing at VaxInnate Corporation, and has previously served as VP of US operations and later VP of global biologics manufacturing at Lonza Biologics.
His previous roles also include VP of manufacturing at BioReliance and VP of manufacturing and pharmaceutical support at EntreMed.
Related Content
Bio-Techne opens GMP small-molecule manufacturing facility in Bristol
Bio-Techne has opened a new facility in Bristol manufacturing Good Manufacturing Practice (GMP)-grade small molecules …
Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
